AMPH stock icon

Amphastar Pharmaceuticals
AMPH

$40.49
0.34%
 

About: Amphastar Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the company sells insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has two reportable segments finished pharmaceutical products and API products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.

Employees: 1,761

0
Funds holding %
of 6,689 funds
Analysts bullish %
0
News positive %
of 6 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

0.19% more ownership

Funds ownership: 69.51% [Q4 2023] → 69.7% (+0.19%) [Q1 2024]

0% more funds holding in top 10

Funds holding in top 10: 3 [Q4 2023] → 3 (+0) [Q1 2024]

1% less call options, than puts

Call options by funds: $2.49M | Put options by funds: $2.52M

4% less funds holding

Funds holding: 274 [Q4 2023] → 263 (-11) [Q1 2024]

14% less repeat investments, than reductions

Existing positions increased: 85 | Existing positions reduced: 99

20% less first-time investments, than exits

New positions opened: 44 | Existing positions closed: 55

29% less capital invested

Capital invested by funds: $2.06B [Q4 2023] → $1.47B (-$588M) [Q1 2024]

Research analyst outlook

1 Wall Street Analyst provided 1 year price forecasts over the past 6 months

Low target
$60
48%
upside
Avg. target
$60
48%
upside
High target
$60
48%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
JP Morgan
Ekaterina Knyazkova
48%upside
$60
Overweight
Initiated
5 Mar 2024

Financial journalist opinion

Based on 6 articles about AMPH published over the past 30 days